patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_336947 | REC_0010901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 7.1 | 65 | female | 0 | 12 | 6 | 7 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.582671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565126 | REC_0010902 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 75 | female | 1 | 33 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:35:59.582908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_674704 | REC_0010903 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.3 | 74 | female | 1 | 10 | 7 | 1 | sotorasib 960 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:35:59.583153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154285 | REC_0010904 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 4 | 66 | male | 0 | 8 | 3.7 | 2 | entrectinib 600 mg daily | 29.2 | true | MSS | 2026-03-15T05:35:59.583392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806469 | REC_0010905 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 15.2 | 72 | female | 2 | 17 | 5.2 | 1 | osimertinib 80 mg daily | 17.5 | true | MSI-H | 2026-03-15T05:35:59.583650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812456 | REC_0010906 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.5 | 53 | female | 0 | 19 | 6.7 | 6 | entrectinib 600 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:59.583897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559369 | REC_0010907 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 5.2 | 78 | male | 1 | 18 | 7.5 | 2 | entrectinib 600 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.584198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248903 | REC_0010908 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 12.4 | 51 | female | 0 | 13 | 5.9 | 0 | entrectinib 600 mg daily | 43.2 | false | MSS | 2026-03-15T05:35:59.584584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281248 | REC_0010909 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.3 | 57 | male | 1 | 9 | 3.8 | 6 | alectinib 600 mg BID | 13.1 | true | MSI-H | 2026-03-15T05:35:59.584851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330548 | REC_0010910 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.3 | 61 | male | 1 | 9 | 5.4 | 1 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.585101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939479 | REC_0010911 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.3 | 73 | female | 2 | 6 | 5.8 | 7 | alectinib 600 mg BID | 13.7 | true | MSS | 2026-03-15T05:35:59.585350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415782 | REC_0010912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.5 | 78 | female | 1 | 13 | 6 | 5 | entrectinib 600 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:59.585590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323308 | REC_0010913 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 18.2 | 62 | male | 1 | 19 | 5 | 1 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:59.585846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789505 | REC_0010914 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.2 | 62 | male | 0 | 22 | 4.4 | 8 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.586092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819507 | REC_0010915 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.6 | 75 | male | 0 | 14 | 7.5 | 1 | osimertinib 80 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:59.586337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416796 | REC_0010916 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.3 | 71 | female | 1 | 9 | 5.5 | 5 | alectinib 600 mg BID | 10.6 | true | MSS | 2026-03-15T05:35:59.586580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686132 | REC_0010917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 15.1 | 71 | female | 1 | 14 | 4 | 4 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:59.586853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193024 | REC_0010918 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.6 | 58 | male | 0 | 23 | 6.2 | 2 | osimertinib 80 mg daily | 15.7 | true | MSS | 2026-03-15T05:35:59.587122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918630 | REC_0010919 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.3 | 72 | female | 2 | 13 | 4.7 | 1 | entrectinib 600 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:35:59.587365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573903 | REC_0010920 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 17 | 5.7 | 63 | male | 0 | 9 | 4.6 | 0 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:59.587602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171423 | REC_0010921 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 7.8 | 70 | female | 3 | 2 | 2.4 | 2 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.587956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991917 | REC_0010922 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 3.3 | 66 | female | 0 | 20 | 5.8 | 1 | pembrolizumab 200 mg q3w | 19.1 | false | MSS | 2026-03-15T05:35:59.588243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899249 | REC_0010923 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.8 | 63 | male | 0 | 8 | 2.9 | 7 | alectinib 600 mg BID | 10.5 | false | MSI-H | 2026-03-15T05:35:59.588489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369726 | REC_0010924 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 9.4 | 69 | male | 0 | 9 | 7.2 | 0 | osimertinib 80 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:59.588727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533413 | REC_0010925 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.4 | 64 | male | 1 | 19 | 3.5 | 5 | sotorasib 960 mg daily | 7 | true | MSS | 2026-03-15T05:35:59.588968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643648 | REC_0010926 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 7.9 | 59 | male | 0 | 9 | 5.4 | 1 | sotorasib 960 mg daily | 20 | true | MSS | 2026-03-15T05:35:59.589200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745226 | REC_0010927 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.1 | 71 | female | 1 | 32 | 5.5 | 6 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:35:59.589428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550635 | REC_0010928 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 15 | 12 | 67 | male | 1 | 8 | 5.1 | 0 | sotorasib 960 mg daily | 35 | true | MSS | 2026-03-15T05:35:59.589666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131617 | REC_0010929 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 16.3 | 63 | female | 0 | 19 | 4.7 | 7 | osimertinib 80 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:59.589901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967822 | REC_0010930 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 8.5 | 48 | male | 0 | 18 | 5.3 | 6 | pembrolizumab 200 mg q3w | 16.4 | true | MSS | 2026-03-15T05:35:59.590135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867889 | REC_0010931 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.9 | 72 | female | 0 | 21 | 4.5 | 2 | sotorasib 960 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:59.590367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143142 | REC_0010932 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 21.4 | 72 | female | 1 | 21 | 4.6 | 2 | entrectinib 600 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:59.590604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851927 | REC_0010933 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.1 | 67 | female | 0 | 8 | 4.3 | 1 | alectinib 600 mg BID | 14.8 | true | MSS | 2026-03-15T05:35:59.590832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825662 | REC_0010934 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6 | 81 | female | 2 | 72 | 3.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:59.591119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296011 | REC_0010935 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 14.1 | 74 | female | 2 | 16 | 5.8 | 6 | entrectinib 600 mg daily | 4.7 | true | MSI-H | 2026-03-15T05:35:59.591368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190860 | REC_0010936 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 7 | 78 | female | 1 | 17 | 5.5 | 0 | osimertinib 80 mg daily | 50.1 | false | MSS | 2026-03-15T05:35:59.591599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770529 | REC_0010937 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.5 | 68 | male | 1 | 38 | 6.3 | 5 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:59.591833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221743 | REC_0010938 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 8.3 | 63 | female | 0 | 26 | 3.9 | 0 | entrectinib 600 mg daily | 40.4 | false | MSS | 2026-03-15T05:35:59.592066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100127 | REC_0010939 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 17.8 | 42 | male | 0 | 14 | 6.9 | 1 | sotorasib 960 mg daily | 21.1 | true | MSS | 2026-03-15T05:35:59.592385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751640 | REC_0010940 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 14 | 7.9 | 63 | female | 0 | 68 | 3.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 50.5 | true | MSS | 2026-03-15T05:35:59.592624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967550 | REC_0010941 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 6.7 | 78 | male | 2 | 12 | 5.7 | 2 | pembrolizumab 200 mg q3w | 28.6 | true | MSS | 2026-03-15T05:35:59.592860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500217 | REC_0010942 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 16.6 | 67 | female | 1 | 3 | 4.8 | 6 | entrectinib 600 mg daily | 4.5 | true | MSI-H | 2026-03-15T05:35:59.593095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886234 | REC_0010943 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.2 | 67 | male | 0 | 15 | 6.4 | 1 | sotorasib 960 mg daily | 10 | true | MSI-H | 2026-03-15T05:35:59.593332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467315 | REC_0010944 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.3 | 69 | female | 0 | 18 | 6.4 | 5 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:59.593562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627125 | REC_0010945 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.4 | 84 | female | 2 | 8 | 4.4 | 7 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.593794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311601 | REC_0010946 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 10.2 | 77 | female | 2 | 13 | 6.2 | 0 | sotorasib 960 mg daily | 39.1 | true | MSS | 2026-03-15T05:35:59.594025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510260 | REC_0010947 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 9.5 | 68 | female | 1 | 11 | 6.9 | 2 | sotorasib 960 mg daily | 30 | true | MSS | 2026-03-15T05:35:59.594316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201817 | REC_0010948 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.5 | 59 | female | 1 | 6 | 3.2 | 7 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:59.594554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305110 | REC_0010949 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 4.2 | 61 | male | 0 | 17 | 5.6 | 1 | alectinib 600 mg BID | 6.8 | false | MSS | 2026-03-15T05:35:59.594786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861874 | REC_0010950 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.9 | 68 | female | 1 | 21 | 4.3 | 6 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.595017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334348 | REC_0010951 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 15.3 | 72 | female | 1 | 11 | 6.4 | 0 | osimertinib 80 mg daily | 41.3 | true | MSS | 2026-03-15T05:35:59.595251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430237 | REC_0010952 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 5.6 | 64 | female | 0 | 16 | 8.1 | 7 | entrectinib 600 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:59.595481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384379 | REC_0010953 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.5 | 64 | female | 0 | 49 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.1 | true | MSS | 2026-03-15T05:35:59.595713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976631 | REC_0010954 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.8 | 60 | female | 1 | 15 | 4.8 | 6 | sotorasib 960 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:59.595949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947506 | REC_0010955 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.2 | 64 | female | 1 | 59 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.6 | false | MSS | 2026-03-15T05:35:59.596266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995734 | REC_0010956 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.9 | 77 | female | 1 | 18 | 5.1 | 3 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.596513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488912 | REC_0010957 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.3 | 69 | female | 0 | 16 | 4.9 | 5 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:59.596746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659458 | REC_0010958 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.8 | 80 | male | 1 | 48 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.9 | false | MSS | 2026-03-15T05:35:59.596979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540820 | REC_0010959 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11 | 64 | male | 1 | 18 | 5.3 | 5 | osimertinib 80 mg daily | 17.5 | true | MSS | 2026-03-15T05:35:59.597219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137620 | REC_0010960 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7.5 | 65 | female | 1 | 17 | 4.2 | 2 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:59.597501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124433 | REC_0010961 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.5 | 77 | female | 2 | 8 | 3.7 | 3 | sotorasib 960 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:35:59.597737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947731 | REC_0010962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.6 | 67 | female | 1 | 18 | 6.7 | 3 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.597971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360764 | REC_0010963 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 7.3 | 80 | male | 1 | 16 | 3.3 | 2 | alectinib 600 mg BID | 27.9 | false | MSS | 2026-03-15T05:35:59.598202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934834 | REC_0010964 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 9.8 | 85 | female | 1 | 18 | 4.3 | 5 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:35:59.598429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927294 | REC_0010965 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 10.6 | 72 | female | 1 | 10 | 6.2 | 5 | pembrolizumab 200 mg q3w | 10.9 | false | MSI-H | 2026-03-15T05:35:59.598663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_199154 | REC_0010966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11.2 | 81 | female | 0 | 14 | 3.4 | 5 | alectinib 600 mg BID | 6.6 | false | MSS | 2026-03-15T05:35:59.598905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600662 | REC_0010967 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 8.6 | 64 | male | 1 | 35 | 2.8 | 2 | pembrolizumab 200 mg q3w | 23.2 | true | MSS | 2026-03-15T05:35:59.599142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791286 | REC_0010968 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 8.7 | 73 | female | 1 | 9 | 6.5 | 7 | alectinib 600 mg BID | 13.1 | false | MSS | 2026-03-15T05:35:59.599374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254455 | REC_0010969 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 18 | 13 | 66 | female | 1 | 16 | 5.1 | 0 | osimertinib 80 mg daily | 28.1 | true | MSS | 2026-03-15T05:35:59.599606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_654176 | REC_0010970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12.9 | 53 | male | 0 | 12 | 5.7 | 2 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:59.599839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795517 | REC_0010971 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 75 | female | 0 | 52 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.7 | true | MSS | 2026-03-15T05:35:59.600067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347257 | REC_0010972 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.5 | 55 | male | 1 | 12 | 6 | 5 | entrectinib 600 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:59.600344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200715 | REC_0010973 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8 | 50 | female | 0 | 1 | 4.2 | 4 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.600655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147600 | REC_0010974 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.8 | 85 | female | 2 | 12 | 3.3 | 6 | alectinib 600 mg BID | 9.3 | false | MSI-H | 2026-03-15T05:35:59.600909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744038 | REC_0010975 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.2 | 85 | male | 1 | 17 | 6.4 | 5 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.601160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530154 | REC_0010976 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.2 | 60 | male | 0 | 13 | 5.6 | 4 | pembrolizumab 200 mg q3w | 11.1 | true | MSS | 2026-03-15T05:35:59.601401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761616 | REC_0010977 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.4 | 65 | male | 1 | 10 | 4.8 | 5 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.601643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673026 | REC_0010978 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.9 | 69 | female | 1 | 26 | 4.9 | 2 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:59.601878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888281 | REC_0010979 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.2 | 64 | female | 1 | 25 | 6.2 | 6 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:59.602117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883057 | REC_0010980 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 9.6 | 64 | male | 1 | 11 | 3 | 1 | sotorasib 960 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:59.602348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291532 | REC_0010981 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 11 | 67 | female | 0 | 14 | 5.9 | 8 | pembrolizumab 200 mg q3w | 15.9 | false | MSI-H | 2026-03-15T05:35:59.602580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271085 | REC_0010982 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.4 | 75 | female | 2 | 17 | 4.5 | 7 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:59.602814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380778 | REC_0010983 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 20.9 | 69 | female | 0 | 13 | 4.9 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:59.603047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599848 | REC_0010984 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 13.9 | 64 | female | 1 | 21 | 7.3 | 5 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:59.603286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820540 | REC_0010985 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.7 | 66 | male | 1 | 13 | 4.8 | 7 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:59.603516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553337 | REC_0010986 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.8 | 59 | male | 1 | 21 | 5.7 | 8 | pembrolizumab 200 mg q3w | 9.2 | true | MSS | 2026-03-15T05:35:59.603827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869742 | REC_0010987 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.3 | 69 | male | 1 | 9 | 6.1 | 3 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:35:59.604066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519751 | REC_0010988 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 7.2 | 72 | male | 1 | 19 | 4.9 | 1 | osimertinib 80 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:59.604349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709863 | REC_0010989 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 9.7 | 67 | male | 0 | 17 | 8.3 | 1 | entrectinib 600 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:59.604585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363848 | REC_0010990 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.5 | 64 | male | 0 | 39 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.9 | false | MSS | 2026-03-15T05:35:59.604819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521506 | REC_0010991 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 15 | 55 | female | 1 | 18 | 6.4 | 1 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:59.605057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113396 | REC_0010992 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.1 | 58 | male | 0 | 25 | 4.6 | 8 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:35:59.605292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228830 | REC_0010993 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9.3 | 83 | female | 3 | 15 | 6.8 | 1 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:59.605527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998570 | REC_0010994 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 19.1 | 54 | female | 0 | 14 | 5.6 | 1 | osimertinib 80 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:59.605765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802521 | REC_0010995 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 14.4 | 59 | male | 0 | 25 | 3.1 | 7 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.606006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803212 | REC_0010996 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.6 | 66 | male | 0 | 12 | 5 | 7 | osimertinib 80 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:59.606257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772666 | REC_0010997 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 11.2 | 75 | female | 2 | 17 | 4.8 | 1 | entrectinib 600 mg daily | 21.1 | false | MSI-H | 2026-03-15T05:35:59.606510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177583 | REC_0010998 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 14.6 | 73 | male | 0 | 2 | 5 | 8 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:59.606781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414232 | REC_0010999 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 6.1 | 76 | female | 1 | 18 | 8.6 | 1 | osimertinib 80 mg daily | 17.7 | false | MSS | 2026-03-15T05:35:59.607137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313180 | REC_0011000 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.9 | 71 | female | 1 | 26 | 5.2 | 1 | entrectinib 600 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:59.607399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.